Wrapping up Q3 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including GoodRx ...

Analysts have recently evaluated GoodRx Holdings and provided 12-month price targets. The average target is $4.16, accompanied by a high estimate of $6.00 and a low estimate of $2.75. This current ...

Fintel reports that on January 22, 2026, Jefferies downgraded their outlook for GoodRx Holdings (NasdaqGS:GDRX) from Buy to ...

Seeking Alpha is built by investors, for investors, so you can get the insights you need to make smarter investing decisions.

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

It has had strong momentum since November, but there is still plenty of upside left.

Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock. ImmunityBio ( ...

Top pharma stocks by Quant Ratings: see Strong Buy/Buy picks across PJP/XPH/PPH—plus why Moderna surged on new cancer-trial ...

German American Bancorp Inc (GABC) is expected to report $0.91 for 4Q. Kayne Anderson Energy Infrastructure Fund Inc (KYN) is expected to report for Full year. LINKBANCORP Inc (LNKB) is expected to ...

In a notable assessment for ServisFirst Bancshares, Inc. (NASDAQ: SFBS), analyst Steve Moss from Raymond James issued a “Strong Buy” rating on January 21, 2026, signaling renewed investor confidence ...